Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results

Drug licensing Financial outlook AI-generated analysis

📈 RS Large Cap Value Strategy highlighted Regeneron Pharmaceuticals (REGN) as a notable contributor in its Q3 2026 investor letter due to solid financial results.

💊 The key drug Dupixent continues to outpace both the fund's and the market's growth expectations, anchoring the company's strong trajectory.

🔄 Regeneron leaned harder into share repurchases in the second quarter when its stock price was deeply discounted.

🤝 A reset deal with partner Sanofi on Dupixent is expected to be accretive to value per share following the quarter-end announcement.

💰 As of October 16, 2026, Regeneron shares closed at $810.31 with a market capitalization of $83.43 billion.

📉 The stock declined 1.64% over the past month but gained 36.12% over the past 52 weeks.

🧠 Longleaf Partners acknowledges Regeneron's potential but currently believes certain AI stocks offer greater upside potential with less downside risk.

Bullish Signals
  • Dupixent continues to outpace both the fund's and the market's growth expectations, demonstrating strong commercial performance.
  • The company leaned harder into share repurchases in the second quarter when its stock price was deeply discounted, signaling confidence in intrinsic value.
  • A reset deal with partner Sanofi on Dupixent is expected to be accretive to value per share, providing a positive financial impact.
Risk Factors
  • The fund currently believes certain AI stocks offer greater upside potential and carry less downside risk compared to Regeneron.
  • Hedge fund holdings of Regeneron decreased from 72 portfolios in the previous quarter to 63 at the end of the second quarter.
Full Analysis
Longleaf Partners' RS Large Cap Value Strategy highlighted Regeneron Pharmaceuticals (REGN) as a notable contributor in its Q3 2026 investor letter, citing the company's solid financial results driven by its key drug Dupixent. The firm noted that Dupixent continues to outpace both internal and market growth expectations, reinforcing the asset's strong trajectory despite broader macroeconomic headwinds like higher interest rates. The investment manager expressed encouragement regarding Regeneron's strategic shift toward share repurchases in the second quarter when its stock price was discounted. Additionally, the firm indicated that a reset deal with partner Sanofi on Dupixent, which occurred after the quarter ended, is expected to be accretive to value per share, further supporting the company's financial outlook. As of October 16, 2026, Regeneron shares closed at $810.31 with a market capitalization of $83.43 billion. While the stock declined 1.64% over the past month, it has gained 36.12% over the last 52 weeks. The fund acknowledges the potential of Regeneron but currently views certain AI stocks as offering greater upside with less downside risk.